RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Conditional marketing approval (China), Special Review Project (China), Orphan Drug (Japan), Orphan Drug (South Korea), Conditional marketing approval (European Union), Orphan Drug (United Kingdom), Breakthrough Therapy (China), Priority Review (United States), Priority Review (China)

Structure/Sequence

Sequence Code 13031374

Source: *****

Clinical Trials associated with Ciltacabtagene autoleucel

NCT07725406

/ Not yet recruitingPhase 1IIT

A Phase Ib, Dose-Escalation Study of Augmented Lymphodepletion and CAR T-cell Priming With Low-dose Total Body Irradiation in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphomas and Multiple Myeloma Receiving Treatment With Commercial CD19 or BCMA-directed CAR T-cell Therapies

This is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD-TBI) in patients with previously treated large B-cell lymphoma (LBCL) or multiple myeloma (MM). The investigators' hypothesis is that the combination will make the immune system more active in fighting cancer by increasing the display of antigens and activating pathways that lead to cell death, including death receptors like FAS and TRAIL2. This approach is expected to help the CAR T cells grow and last longer, leading to stronger anti-tumor effects and more cancer cell deaths. Participants will receive LDTBI treatment before their CAR T cell therapy and will be followed up for 2 years.

Start Date01 Aug 2026

Sponsor / Collaborator

Weill Medical College of Cornell University

NCT07093554

/ RecruitingPhase 1IIT

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

This is a single-arm, open-label, phase 1b study evaluating the safety and feasibility of using talquetamab as bridging therapy prior to cilta-cel in patients with relapsed and refractory multiple myeloma (RRMM).

Start Date02 Dec 2025

Sponsor / Collaborator

Medical College of Wisconsin

NCT07149857

/ RecruitingPhase 2

A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel

The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilta-cel infusion following a cyclophosphamide and fludarabine lymphodepletion regimen.

Start Date03 Oct 2025

Sponsor / Collaborator

Janssen Research & Development LLC

100 Clinical Results associated with Ciltacabtagene autoleucel

100 Translational Medicine associated with Ciltacabtagene autoleucel

100 Patents (Medical) associated with Ciltacabtagene autoleucel

438

Literatures (Medical) associated with Ciltacabtagene autoleucel

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Real-world healthcare resource utilization and clinical outcomes among patients with relapsed/refractory multiple myeloma receiving ciltacabtagene autoleucel after four or more prior lines of therapy in inpatient versus outpatient settings

Article

Author: Maitland, Jessica ; Perciavalle, Matthew ; Janakiram, Murali ; Nagar, Saurabh P. ; Ghosh, Sabyasachi ; Bixby, Todd ; Fan, Lin ; Dima, Danai ; Qureshi, Zaina P. ; Emond, Bruno ; Alegria, Victoria

BACKGROUND:

Ciltacabtagene autoleucel (cilta-cel) has demonstrated remarkable efficacy in relapsed or refractory multiple myeloma (RRMM). Outpatient (OP) administration of cilta-cel is increasingly used to improve access and reduce healthcare resource utilization (HCRU) compared to inpatient (IP) administration. We compared all-cause HCRU and clinical outcomes of IP versus OP administration of cilta-cel in patients with RRMM after ≥4 prior lines of therapy (LOT) in clinical practice.

METHODS:

We identified adults receiving cilta-cel between 02/28/2022 and 06/30/2024 after ≥4 prior LOT using Komodo Research Database claims data and classified patients into cohorts by setting of administration (IP/OP). All-cause HCRU, treatment-free interval (TFI), overall survival (OS), and clinical events (e.g. cytokine release syndrome [CRS], immune effector cell-associated neurotoxicity syndrome [ICANS]) were assessed. Outcomes were compared using multivariate regression and reported as incidence rate ratios (IRR) with 95% confidence intervals (CI).

RESULTS:

Among 242 patients, 148 (61.2%) received cilta-cel in IP and 94 (38.8%) in OP. Baseline characteristics were comparable between cohorts. Of patients in the OP cohort, 31.9% did not require an IP admission within 3 months post-infusion. During this period, the OP cohort had significantly fewer IP days per-patient-per-month (2.4 vs. 6.6; IRR [95% CI]: 0.37 [0.28; 0.48], p < 0.001) and more OP days (8.5 vs 5.4; IRR [95% CI]: 1.43 [1.26; 1.63], p < 0.001) than the IP cohort. From the fourth month post-infusion, no significant differences in HCRU were observed. Rates of CRS and ICANS, and long-term outcomes including 6 and 12 month TFI and OS were similar.

CONCLUSION:

OP administration of cilta-cel yielded similar effectiveness and safety outcomes relative to IP administration, while significantly reducing IP resource use. These findings support the feasibility of OP administration of cilta-cel in treating RRMM patients and its potential to reduce the burden on the healthcare system.

14 Jul 2026·Blood Advances

Diagnosis and management of immune effector cell–associated enterocolitis after ciltacabtagene autoleucel

Article

Author: Bledsoe, Adam ; Gertz, Morie ; Lin, Yi ; Ailawadhi, Sikander ; Chen, Zongming Eric ; Chowla, Navreet ; Lim, Kenneth J. C. ; Geyer, Susan ; Kourelis, Taxiarchis ; Warsame, Rahma ; Chhabra, Saurabh ; Tan, Melinda ; Bergsagel, P. Leif ; Hwa, Lisa ; Kapoor, Prashant ; Lee, Hee Eun ; Binder, Moritz ; Dooley, Katharine ; Parrondo, Ricardo ; Yadav, Udit ; Cook, Joselle ; Kumar, Shaji ; De Menezes Silva Corraes, Andre ; Stephens, Haily ; Fonseca, Rafael ; Wiedmeier-Nutor, Erin

Abstract:

Immune effector cell–associated enterocolitis (IEC-EC) has been observed after ciltacabtagene autoleucel (cilta-cel [Carvykti]) chimeric antigen receptor T-cell (CAR-T) therapy. It is associated with dismal outcomes and is poorly characterized. Here, we examined its clinical features, risk factors, and proposed management strategies. Among the 229 consecutive patients who received cilta-cel at Mayo Clinic, 9 (3.9%) presented with a nonresolving, nonbloody, grade 3 diarrhea, often requiring prolonged total parenteral nutrition. Gastrointestinal coinfections were seen in most patients. Median time from CAR-T infusion to symptom onset was 85 days (range, 35-166), and there appeared to be a latency from symptom onset to endoscopic evaluation. Histopathology findings resembling a graft-versus-host disease pattern of mucosal injury were most seen on duodenal biopsies, whereas 2 cases had patterns akin to a T-cell lymphoproliferative disorder (1 CD4+ and 1 CD8+). Independent associated factors for IEC-EC included high-risk disease as defined by the International Myeloma Society and International Myeloma Working Group, prolonged cytokine release syndrome, and antecedent delayed neurotoxicity. Response to first-line therapy comprising IV or oral corticosteroids, bile acid sequestrants, IV immunoglobulin, and antimicrobial-directed therapy was poor, with no durable responses. Biologic therapy appeared to induce durable responses in 3 of the 5 patients (2/2 vedolizumab; 1/3 infliximab); none of the responders had gastrointestinal coinfection. Early gastroenterology input for endoscopic evaluation with the inclusion of duodenal biopsy is a key component for diagnosis. Early institution of biologic therapy after failure of a short course of corticosteroids should be considered.

01 Jul 2026·AMERICAN JOURNAL OF HEMATOLOGY

Navigating the Post‐ BCMA / GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta‐Refractory Multiple Myeloma—A Multicenter Analysis

Article

Author: Bartke, Leandra ; Harzer, Marie ; Brioli, Annamaria ; Khandanpour, Cyrus ; Cords, Leon ; Hillmann, Stefan M. ; Al‐Bazaz, Maximilian ; Weisel, Katja ; Bokemeyer, Carsten ; Holtick, Udo ; Artzenroth, Jule ; Kamili, Abdulaziz ; Leypoldt, Lisa ; Schaefers, Christoph ; Vorwerk, Jan ; Leitner, Theo ; Salwender, Hans ; Sonnemann, Piet ; Maulhardt, Markus ; Brinkert, Kerstin ; Kosch, Ricardo ; Richardson, Tim ; Alsdorf, Winfried

ABSTRACT:

Patients with relapsed/refractory multiple myeloma (RRMM) who are penta‐drug refractory, defined as resistant to two proteasome inhibitors, two immunomodulatory agents, and an anti‐CD38 monoclonal antibody, face a dismal prognosis, particularly after exposure to T‐cell–redirecting therapies. Selinexor, an oral exportin‐1 inhibitor, offers a distinct mechanism of action and may retain efficacy in this difficult setting. We conducted a retrospective analysis at six German tertiary centers (2023–2025) to evaluate the efficacy and safety of selinexor plus bortezomib and dexamethasone (SVd) in penta‐refractory MM after both BCMA‐ and GPRC5D‐targeted therapies. Eighteen patients were identified, with a median of seven prior lines of therapy. High‐risk cytogenetic abnormalities were present in seven cases, including del17p in six. The overall response rate (ORR) was 61%, including one complete, five very good partial, and five partial responses, and median progression‐free survival (PFS) was 4.3 months. Among nine patients (50%) with extramedullary disease (EMD), three achieved complete and one near‐complete EMD resolution. Two patients who had relapsed after CAR T‐cell treatment with idecabtagene vicleucel achieved partial and very good partial responses and were successfully transitioned to a second CAR T‐cell therapy with ciltacabtagene autoleucel. Hematologic toxicities under SVd were manageable, and no treatment‐related deaths occurred. SVd demonstrates meaningful activity in patients with penta‐refractory MM and prior failure of BCMA/GPRC5D‐targeted immunotherapies. The ORR of 61%, disease control in 78% of patients, and median PFS of 4.3 months support further evaluation of SVd in this highly refractory setting after failure of BCMA‐ and GPRC5D‐directed approaches.

553

News (Medical) associated with Ciltacabtagene autoleucel

27 Jul 2026

·www.fiercebiotech.com

Legend Biotech CEO abruptly steps down without permanent replacement

In a sudden leadership shift, Legend Biotech announced that its CEO, Ying Huang, Ph.D., resigned on Friday, with no permanent replacement yet named. After Huang handed in his notice, Legend’s board appointed Alan Bash as the company’s interim CEO on July 23, an SEC filing (PDF) shows. A “comprehensive search process to identify a permanent successor” is underway, the company said in a July 27 press release. Bash joined Legend as president of Carvykti in 2024, four years after Huang’s elevation from CFO to CEO when the company’s founder Fangliang Zhang, Ph.D., was under investigation in China over customs issues. Zhang returned to his post as Legend’s chairman in 2022 as authorities closed the probe without any charges. In his role, Bash has been managing Legend’s commercial operations, specifically, Carvykti, the Johnson & Johnson-partnered multiple myeloma CAR-T therapy, which is the bread and butter of Legend’s business. Huang’s resignation “was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices or the Company’s financial statements or internal controls over financial reporting,” Legend said in a July 27 SEC filing. Huang will remain as an advisor through August to support a smooth transition. That seemingly amicable exit stands in contrast to Legend’s past leadership drama, notably its messy split with scientific co-founder and former chief scientific officer, Frank Fan, M.D., Ph.D., in 2022, which triggered lawsuits that eventually didn’t go Legend’s way. “On behalf of the Board, I want to thank Ying for his leadership, dedication and many contributions to Legend Biotech during the past seven years,” Zhang said in a July 27 statement. “During his tenure, Legend Biotech advanced from a pioneering cell therapy company into a global leader with a strong commercial foundation, a differentiated innovation platform, and a clear commitment to patients. We are grateful for Ying’s continued support through the transition and wish him well in his next chapter.” As for Bash, his “immediate focus will be on ensuring continuity across the business, maintaining strong execution, and supporting our teams as we continue advancing our commercial, clinical, and operational priorities,” according to a statement. In the past two years or so, Legend has come under pressure from potential competition to Carvykti, as well as geopolitical risks given its ties to China. Legend’s stock price hit its lowest in years in February amid ongoing concerns regarding rival treatments such as Gilead Sciences’ CAR-T candidate anito-cel and J&J’s bispecific antibody regimens. Legend’s shares enjoyed a rally in early June after the company reported encouraging early-phase data for LB2501, a CD19/CD20 dual-targeting in vivo CAR-T therapy. Data revealed at the 2026 American Society of Clinical Oncology included a 100% objective response rate at the highest-dose cohort of six patients with pretreated B-cell non-Hodgkin lymphoma, an 83.3% complete response rate, with a relatively clean safety profile without any serious adverse events or neurotoxicity. However, the company’s stock price has since fallen back to pre-ASCO levels as concerns over Carvykti’s market position and the lack of mid- to late-stage pipeline assets took hold again. On July 15, while partner J&J reported another record quarter of Carvykti sales that roughly met analysts’ expectations, Legend’s shares dropped 10% . On J&J’s earnings call that day, Jennifer Taubert, worldwide chair of innovative medicine, described the company’s off-the-shelf combination of Tecvayli and Darzalex as holding “the potential for cure” in previously treated myeloma. Then on July 23, the day that Bash was named interim CEO of Legend, J&J reported jaw-dropping efficacy from its dual-bispecific combination of Tecvayli and Talvey. Compared with standard of care, the two T-cell engagers improved progression-free survival by 89% and overall survival by 62% in earlier-line myeloma.

Executive ChangeClinical ResultASCO

27 Jul 2026

·firstwordpharma.com

Legend CEO exit puts company's Carvykti leader at the helm

Legend Biotech is searching for a new chief executive after Ying Huang stepped down from his roles as CEO and board member. The company has named Alan Bash, current head of the business unit for Carvykti (ciltacabtagene autoleucel), its BCMA-directed CAR-T therapy developed with Johnson & Johnson, as interim chief executive.Huang's resignation became effective July 24, and the company said he will remain as an advisor through August to support a smooth transition."As I prepare for my next chapter, I've been reflecting on what has made the past seven years at Legend Biotech so meaningful," Huang said in a LinkedIn post Monday. "Together, we helped advance cell therapy and expand treatment options for people living with multiple myeloma… I leave with deep confidence in the future of Legend Biotech."Huang joined Legend as chief financial officer in 2019 and was promoted to CEO the following year.Meanwhile, Bash brings commercial and operational experience to the interim role, having led Legend's Carvykti business since October 2024. The company's sole marketed product, the CAR-T therapy was first approved in 2022 for heavily pre-treated multiple myeloma patients and eventually also for use in the second-line setting in both the US and EU. J&J said last week that Carvykti generated sales of $657 million in its most recent reported quarter, a jump of nearly 50% from the year-ago period."My immediate focus will be on ensuring continuity across the business, maintaining strong execution, and supporting our teams as we continue advancing our commercial, clinical, and operational priorities," Bash said in a company release.Before joining Legend, Bash served as CEO of ZielBio and Checkmate Pharmaceuticals and spent more than 22 years at Bristol Myers Squibb, where he held multiple leadership positions.A search is now underway for a permanent successor to Huang at Legend's helm. Despite the unexpected leadership change, Raymond James analyst Sean McCutcheon said he still views Legend's fundamentals as strong and sees substantial upside to the current share price.

Executive ChangeDrug ApprovalCell Therapy

27 Jul 2026

·www.biospace.com

Legend Biotech Announces CEO Transition

Ying Huang, Ph.D., steps down as Chief Executive Officer and member of the Board of Directors; will remain as an advisor through August to support a smooth transition Alan Bash, current President of the CARVYKTI Business Unit, appointed Interim Chief Executive Officer Board has initiated a comprehensive search process to identify a permanent successor BRIDGEWATER, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global leader in cell therapy, today announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and as a member of the Board of Directors, effective as of July 24, 2026. Dr. Huang will remain as an advisor through August to support a smooth transition. The Board has appointed Alan Bash, current President of the CARVYKTI Business Unit, as Interim Chief Executive Officer. The Board has also initiated a comprehensive search process to identify a permanent successor. “On behalf of the Board, I want to thank Ying for his leadership, dedication and many contributions to Legend Biotech during the past seven years,” said Frank Zhang, EMBA, Ph.D., Chairman of the Board of Legend Biotech. “During his tenure, Legend Biotech advanced from a pioneering cell therapy company into a global leader with a strong commercial foundation, a differentiated innovation platform, and a clear commitment to patients. We are grateful for Ying’s continued support through the transition and wish him well in his next chapter.” Dr. Zhang continued, “The Board has full confidence in Alan’s ability to provide continuity and disciplined execution during this period. Alan has deep knowledge of our business, significant commercial and operational experience, and a strong understanding of the opportunity ahead. We remain focused on advancing our priorities, supporting continued growth, and ensuring Legend Biotech is well positioned to deliver on its mission for patients.” ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); “It has been a privilege to lead Legend Biotech and to work alongside such a talented and committed team,” said Dr. Huang. “I am deeply grateful to my colleagues, the Board and our partners for their dedication, resilience and shared commitment to patients. Together, we have helped advance cell therapy in meaningful ways and built a strong foundation for the company’s future. I remain highly confident in the Company’s strategy, pipeline and long-term growth opportunities. Our priorities are clear, our strategy is unchanged, and we are focused on execution. I look forward to supporting a smooth transition and watching Legend Biotech continue to make an important impact for patients and families.” “I am honored to step into the role of Interim CEO and grateful for the Board’s confidence,” said Mr. Bash. “Legend Biotech has a clear mission, a strong team and important opportunities ahead. My immediate focus will be on ensuring continuity across the business, maintaining strong execution, and supporting our teams as we continue advancing our commercial, clinical, and operational priorities. We remain committed to bringing innovative cell therapies to more patients around the world.” ABOUT LEGEND BIOTECH With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI ® , a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities. Learn more at and follow us on X and LinkedIn . CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Legend Biotech’s continued execution and advancement of commercial, clinical and operational priorities, strategy and long-term growth opportunities. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2026. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise. INVESTOR CONTACT: Caroline Paul Tel: 973-650-5832 investor@legendbiotech.com PRESS CONTACT: Kim Fox Tel: (848) 388-8445 media@legendbiotech.com

Executive ChangeCell Therapy

100 Deals associated with Ciltacabtagene autoleucel

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Refractory Multiple Myeloma	Japan	Janssen Pharmaceutical KK	03 Aug 2022
Relapse multiple myeloma	Japan	Janssen Pharmaceutical KK	03 Aug 2022
Multiple Myeloma	United States	Nanjing Legend Biotech Co., Ltd.	28 Feb 2022
Multiple Myeloma	United States	Janssen Biotech, Inc.	28 Feb 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Smoldering Multiple Myeloma	Phase 2	United States	Janssen Research & Development LLC	19 Apr 2023
Recurrent Multiple Myeloma	Phase 2	-	Nanjing Legend Biotech Co., Ltd.	02 Oct 2015
Extramedullary Disease in Multiple Myeloma	Phase 1	Australia	Janssen LP	08 Dec 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2026	Not Applicable	Multiple Myeloma	60	Prophylactic cyclophosphamide (PPX CTX)	xscfncresz(qjnbjvwpds) = PPX CTX was well tolerated, with 2 cases of grade 1 nausea reported. rjyawkadvd (sxegowifxa )	Negative	29 May 2026
				Prophylactic dexamethasone (PPX DEX)
NCT04181827 (CARTITUDE-4, ASCO2026)	Phase 2	Refractory Multiple Myeloma	104	Ciltacabtagene autoleucel (High-risk cytogenetics)	heupetdjxb(vvwbtlnter) = vxotxepdgd zdiyopieup (ylxaqhvmpi ) View more	Positive	29 May 2026
				Ciltacabtagene autoleucel (Standard-risk cytogenetics)	heupetdjxb(vvwbtlnter) = sctumiwala zdiyopieup (ylxaqhvmpi ) View more
NCT04181827 (CARTITUDE-4, EHA2026)	Phase 2	Refractory Multiple Myeloma	104	CILTACABTAGENE AUTOLEUCEL (high-risk cytogenetics)	pjdniilavg(wlfxatlwcg) = ddcfqbkfdc rmukjldfui (xuflxsvpve ) View more	Positive	21 May 2026
				CILTACABTAGENE AUTOLEUCEL (standard-risk cytogenetics)	pjdniilavg(wlfxatlwcg) = sooylgytez rmukjldfui (xuflxsvpve ) View more
ASGCT2026	Not Applicable	B-Cell Leukemia \| B-Cell Lymphoma \| Multiple Myeloma ... View more	469	Idecabtagene vicleucel (Abecma)	pxeuastpaf(yurqktunra) = htjkkyecoi gqvrswqrmq (vvktcpnsub ) View more	Positive	13 May 2026
				Lisocabtagene maraleucel (Breyanzi)	pxeuastpaf(munfsdusgp) = bpkgopuygd mplttwmyxh (zcjwqmpahs )
EHA2026	Not Applicable	Refractory Multiple Myeloma	345	Ciltacabtagene autoleucel (cilta-cel)	ueziegfswd(awspvdzskj) = xzwplgzxzu jlswyyxxqv (hhzkdqhwiz ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Relapse multiple myeloma	12	Ciltacabtagene autoleucel (cilta-cel)	ztmowdimld(pgdlhpxxyi) = heytthgvul arczsjiakf (qwcveslxfl ) View more	Positive	12 May 2026
EHA2026	Not Applicable	Multiple Myeloma	250	OOS anti-BCMA CAR-T	dlxltjtskr(wcdrykylba) = vbmwoazozm owcqxhjgji (vebakgonay ) View more	Positive	12 May 2026
				IS anti-BCMA CAR-T	dlxltjtskr(wcdrykylba) = sucalfjxgw owcqxhjgji (vebakgonay ) View more
NCT05767359 (CAR-PRISM, Pubmed \| Nat Med)	Phase 2	Smoldering Multiple Myeloma	20	Ciltacabtagene autoleucel	fzjketpqdm(jxgfcyxogp) = Adverse events included transient cytopenias (90% grade 3/4) and cytokine release syndrome (100% grade 1/2). Non-immune effector cell-associated neurotoxicity syndrome neurologic toxicities (NINTs) occurred in seven patients, with four comprising cranial nerve palsies that completely resolved. Three patients had persistent grade 1 symptoms. wsqwffxxqp (lvyqqmazjm )	Positive	20 Apr 2026
NCT04181827 (CARTITUDE-4, EBMT2026)	Phase 3	Relapse multiple myeloma	196	CILTACABTAGENE AUTOLEUCEL	xyjofjmllp(zoztgkvusd) = Cranial nerve palsy was reported in 11.9%, 7.1%, 8.2% and 5.0% of patients with ≥VGPR, PR, MR/SD and PD, respectively. dffgwthywn (ixiflyzuvu ) View more	Positive	22 Mar 2026
NCT04181827 \| NCT03548207 \| NCT03651128 (CARTITUDE-4, Pubmed \| Adv Ther)	Phase 3	Relapse multiple myeloma	221	Cilta-cel	xhzwppgamj(meolpxynrq): RR = 1.22 (95.0% CI, 1.08 - 1.38), P-Value = 0.0126 View more	Superior	01 Mar 2026
				Ide-cel

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Ciltacabtagene autoleucel

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation